glp-1 medication competitors pharmaceutical companies Costs Explained: Managing Coverage Challenges The Next Big Weight Loss

Joy TR, McKenzie CA, Tirona RG et al (2017) Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

Underneath its clinical study results, it lists statistics like 67 percent say their overall health and well-being have improved while 44 percent report clearer thinking and better focus. The survey claims 67 percent have reported better, more regular digestion but that could mean anything from less bloating to more pooping

Climax J, Newsome PN, Hamza M et al (2020) Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers

These medications are well researched, and the majority of patients tolerate them well when treatment is introduced gradually and monitored closely